Regulations, Ripple Effects & Unintended Consequences
3 Key Gaps in the Proposed Drug Import Policy
Stephen Hahn as the next FDA commissioner: What to expect from the agency in 2020
On Novartis' Data Manipulation
The news this past week that scientists at Novartis manipulated data in comparability studies for their gene therapy (Zolgensma) was surprising and disheartening. You can read one of the
“If this is true” - What does this mean for clinical trials?
By Greg Dombal and Niki Gallo, Halloran Consulting Group